You are here: Industry Insights > psoriasis

News List

Novartis confirms 5 year data for first and only fully-human IL-17A inhibitor Cosentyx® reinforcing worldpharmanews
July 17, 2017
Novartis, a global leader in Immunology & Dermatology, confirmed today positive 5 year efficacy and safety results for Cosentyx® from a Phase III long-term extension study in patients with moderate-to-severe plaque psoriasis.
UK GPs lacking in psoriasis training, warns report pharmatimes
May 04, 2017
A new by The Patient Association in association with LEO Pharma has highlighted the significant gap between...
NICE recommends Ixekizumab (Taltz) to treat severe plaque psoriasis pharmaceutical-technology
April 28, 2017
Eli Lilly and Company has announced that UK NICE has recommended the usage of Ixekizumab (Taltz) as an option...
Psoriasis drug Siliq will be cheapest in class, Valeant reveals pharmafile
April 25, 2017
Canadian pharmaceutical firm Valeant has announced the list price for its psoriasis treat Siliq (brodalumab) will stand at $3,500 a month, in an effort to undercut its rivals in the space.
Men More Prone to Severe Psoriasis: Study drugs.com
April 07, 2017
Severe psoriasis is much more common in men than women, a new study from Sweden reports.
New report reveals little progress on 2014 WHO psoriasis recommendations europeanpharmaceuticalreview
April 06, 2017
A new report by the Economist Intelligence Unit (EIU) reveals governments have taken little or no action to improve care for those living with psoriasis.
Tackling inequality in psoriasis lilly
April 05, 2017
This artcle comes from Erin Huntington, VP of International Corporate Affairs at Eli Lilly and Company
Novartis' Cosentyx is first and only IL-17A inhibitor to potentially modify the course of psoriasis worldpharmanews
March 23, 2017
Novartis has announced new data suggesting, for the first time, that Cosentyx® (secukinumab) may modify the course of moderate-to-severe psoriasis leading to long-term, treatment-free skin clearance[1].
Novartis says Cosentyx can potentially modify the course of psoriasis in certain patients firstwordpharma
March 22, 2017
Novartis on Tuesday unveiled data from a Phase III study suggesting that Cosentyx (secukinumab) can alter the course of moderate-to-severe psoriasis resulting in long-term, treatment-free skin clearance in some patients.
Novartis' Cosentyx shows almost all psoriasis patients rapidly regain skin clearance following a tre cphi-online
March 09, 2017
Cosentyx has shown superior and sustained results versus both Stelara and Enbrel, delivering long-lasting clear or almost clear skin.

Previous page 1 2 3 4 5 6 7 8 9 10 Next page